Sunday, September 6, 2015

John C. Lechleiter: Eli Lilly and Company CEO

John C. Lechleiter was born to John and Jeanne Lechleiter on August 17, 1952, in Louisville, Kentucky and is the eldest of nine children.  In 1974, John first took part in laboratory research in a summer research program at the University of Minnesota. 
He earned a Bachelor of Science in Chemistry from Xavier University (Cincinnati, Ohio) in 1975. John was awarded a National Science Foundation fellow and studied Organic Chemistry at Harvard University. He obtained his Master’s degree and PhD in 1980.
In 1979 he joined Lilly as a senior organic chemist in process research and development and in 1982 became head of that department.  John began serving as director of pharmaceutical product development for the Lilly Research Centre Limited in Windlesham, England in 1984. He later held positions in project management, regulatory affairs, product development, and pharma operation. John was appointed president and chief operating officer and joined the board of directors in 2005.
Since April 1, 2008, John has served as president and chief executive officer at Eli Lilly and Company. He was elected chairman of the board of directors in January 1, 2009. 
John is a member of the American Chemical Society and Business Roundtable. He serves on the board of the Pharmaceutical Research and Manufacturers of America (PhRMA), as chairman of the US-Japan Business Council and of United Way Worldwide, and on the boards of the Life Science Foundation and the Central Indiana Corporate Partnership. John also serves on the boards of Nike, Inc. and Ford Motor Company.
He has received Honorary Doctorates from Marian University in 2006, the University of Indianapolis in 2012, and the National University of Ireland also in 2012.  John was bestowed the inaugural Global Health Partner Award from Project HOPE in 2012. He was named in 2014, the August M. Watanabe Life Science Champion of the Year for his work in supporting the development of the Indiana Biosciences Research Institute. 

No comments:

Post a Comment